The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Manufacturing Peptides as Active Pharmaceutical Ingredients
Abstract
BACKGROUND: Today, there are more than 40 peptides on the pharmaceutical world market and more than 100 in several clinical phases. Although in the past the pharmaceutical industries had reduced their interest in peptides research, in recent decades, they have rekindled their interest in peptides as a result of contemporary novel technological accomplishments, strategic developments, advances in the areas of formulation and enhanced drug delivery technology of peptides. Thus, eight new peptide drugs that could previously have been characterized as difficult to prepare on the large scale required by industry, have entered the pharmaceutical market at the new millennium. DISCUSSION: The manufacturing of most of these drugs has benefited from new technological advances. Traditional and most modern techniques have been applied to the manufacture of these new entries. CONCLUSION: Recent accomplishments, together with the traditional benefits of peptides (high biological activity, high specificity and low toxicity), have led pharmaceutical companies to re-focus their attention on peptide-based agents. Therefore, several serious diseases can be treated using the potential next generation of peptide drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Eipper, B. A., Milgram, S. L., Jean Husten, E., Yun, H., & Mains, R. E. (1993) · Protein Science · doi:10.1002/pro.5560020401 · Cited by 270
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Cited by
Advances in Fmoc solid‐phase peptide synthesis
Behrendt, R., White, P., & Offer, J. (2016) · Journal of Peptide Science · doi:10.1002/psc.2836 · Cited by 760
Synthesis of proteins by automated flow chemistry
Hartrampf, N., Saebi, A., Poskus, M., Gates, Z. P., Callahan, A. J., Cowfer, A. E., Hanna, S., Antilla, S., Schissel, C. K., Quartararo, A. J., et al. (2020) · Science · doi:10.1126/science.abb2491 · Cited by 367
Albericio, F., & Kruger, H. G. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.94 · Cited by 307
Self-citationPeptide synthesis beyond DMF: THF and ACN as excellent and friendlier alternatives
Jad, Y. E., Acosta, G. A., Khattab, S. N., de la Torre, B. G., Govender, T., Kruger, H. G., El-Faham, A., & Albericio, F. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02046d · Cited by 92
Solid‐phase peptide synthesis using acetonitrile as a solvent in combination with PEG‐based resins
Acosta, G. A., del Fresno, M., Paradis‐Bas, M., Rigau‐DeLlobet, M., Côté, S., Royo, M., & Albericio, F. (2009) · Journal of Peptide Science · doi:10.1002/psc.1158 · Cited by 63
Self-citation
Metadata
- Authors
- Zompra, A. A., Galanis, A. S., Werbitzky, O., & Albericio, F.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 1
- Issue
- 2
- Pages
- 361-377
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W1972158457
- Cited by
- 170
- References
- 3
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Manufacturing Peptides as Active Pharmaceutical Ingredients. https://app.cochat.ai/papers/10.4155/fmc.09.23
- The paper
- Zompra, A. A., Galanis, A. S., Werbitzky, O., & Albericio, F. (2009). Manufacturing Peptides as Active Pharmaceutical Ingredients. Future Medicinal Chemistry. https://doi.org/10.4155/fmc.09.23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
